Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.340
+0.020 (0.86%)
Jul 22, 2025, 8:29 AM - Market open
Spero Therapeutics Employees
Spero Therapeutics had 32 employees as of December 31, 2024. The number of employees decreased by 14 or -30.43% compared to the previous year.
Employees
32
Change (1Y)
-14
Growth (1Y)
-30.43%
Revenue / Employee
$1,393,250
Profits / Employee
-$2,180,094
Market Cap
130.83M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
SPRO News
- 5 weeks ago - Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results - Seeking Alpha
- 7 weeks ago - Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga
- 7 weeks ago - Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - GlobeNewsWire
- 2 months ago - Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - GlobeNewsWire
- 3 months ago - Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer - GlobeNewsWire
- 4 months ago - Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update - GlobeNewsWire